Human microbiome drugs market to be valued at $2.13b by 2031

By end users, the hospitals & clinics segment held the largest market share in 2024.

The human microbiome drugs market is expected to reach $2.13b by 2031 at a compound annual growth rate of 35.2%, according to MarketsandMarkets.

The sector’s expansion is attributed to the collaboration between CDMOs, biotech firms, and academic institutions to advance bioprocess innovation and scale microbiome research into GMP-compliant production.

Moreover, developments in microbial engineering, high-throughput analytics, and automation improve cultivation control and product consistency, enabling next-generation live biotherapeutics and probiotics.

“Innovations in encapsulation, lyophilisation, and delivery technologies are also increasing the diversity and effectiveness of manufacturable microbiome-based products,” the report said.

By end users, the hospitals & clinics segment accounted for the largest market share in 2024, driven by strong capabilities in trained personnel, infrastructure, and patient engagement for follow-up monitoring.

“The increasing prevalence of chronic diseases and the rising demand for microbiome-targeted treatments further strengthen hospitals and clinics as the foremost end-user ‍‌segment,” it added.